Lee H Y, Yang K H, Choi B H, Park Y M, Yoon K T, Ryu J H, Chu C W
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
Division of Hepatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
Transplant Proc. 2016 Jan-Feb;48(1):247-50. doi: 10.1016/j.transproceed.2015.11.012.
Liver transplantation is a potentially curative treatment for hepatocellular carcinoma. However, patients with recurrent hepatocellular carcinoma after liver transplantation have few treatment options and local treatment may not be feasible. Sorafenib, an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma, significantly improves progression-free and overall survival. However, only a few studies have evaluated the efficacy of sorafenib in patients with recurrent hepatocellular carcinoma following liver transplantation. Here, we report a case of a patient with recurrent advanced hepatocellular carcinoma after living donor liver transplantation who achieved complete remission in response to sorafenib treatment. The patient has survived for more than 4 years post-transplantation.
肝移植是肝细胞癌一种潜在的治愈性治疗方法。然而，肝移植后复发性肝细胞癌患者的治疗选择有限，局部治疗可能不可行。索拉非尼是一种口服活性多激酶抑制剂，已被批准用于治疗晚期肝细胞癌，可显著改善无进展生存期和总生存期。然而，仅有少数研究评估了索拉非尼在肝移植后复发性肝细胞癌患者中的疗效。在此，我们报告1例活体肝移植后复发性晚期肝细胞癌患者，其接受索拉非尼治疗后实现完全缓解。该患者移植后已存活超过4年。
